SGS, a leading bio/pharmaceutical, analytical and bioanalytical contract solutions provider, today announced that it has invested in multiple highly sensitive and selective LC-MS/MS instruments at its Poitiers, France laboratory, for the quantification of proteins and peptide therapeutics. 

The two systems, which are now installed and validated, are a combination of the AB SCIEX 6500+ and Shimadzu X2 UPLC, which offers high specificity, a wide dynamic range, faster method development and the ability to quantify multiple proteins simultaneously. LC-MS/MS techniques have a number of advantages over standard conventions for protein and peptide quantitation, which are based on ligand-binding assays (LBAs) such as the enzyme-linked immunosorbent assay (ELISA). Assay development can often be time-consuming and expensive and, in addition, LBA results are often plagued by interferences and high background from antibody cross-reactivity.

“Mass spectrometry platforms have universal applicability, providing one technique for a large diversity of analytes,” commented Dr. Walid Elbast, Director LC-MS at SGS Poitiers. “All types of proteins and peptides can be quantified by LC/MS/MS without exception, and a wide diversity of other biomolecules such as lipids and carbohydrates can also be quantified, providing researchers with a highly sensitive, selective and flexible bioanalytical platform.”

With 21 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.

For further information, please contact:

McKenzie Landgraf
Life Sciences – Marketing Manager
Agriculture, Food and Life
t: +1 301 556 0863 
www.sgs.com/lifescience
 
Richard Kerns
President
NEPR
t: +44 (0)161 728 5880

About SGS

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognised as the global benchmark for quality and integrity. With more than 90,000 employees, SGS operates a network of over 2,000 offices and laboratories around the world.